Boston Scientific Corp (BSX) · Nov 20, 2026 · New debt
Debt financing — $3.0B USD notes plus €4.25B euro notes
Boston Scientific’s new debt offering funds its planned Penumbra acquisition, improving closing certainty but adding substantial borrowing.
Boston Scientific is a broad medical-device company using the Penumbra acquisition to expand deeper into neurovascular and thrombectomy therapies; the announced transaction carries an enterprise value of about $14.5 billion and is structured roughly 73% in cash and 27% in Boston Scientific shares. This filing turns the acquisition’s funding plan into a priced transaction. Boston Scientific has committed to $3.0 billion of U.S.-dollar notes and €4.25 billion of euro notes, with maturities spanning 2028 to 2046. 〔0〕
| USD offering | Euro offering | |
|---|---|---|
| Principal (Press release) | $3.0B | €4.25B |
| Maturities (Press release) | 2029–2036 | 2028–2046 |
| Coupon range (Press release) | 5.375%–5.875% | 3.875%–5.125% |
The positive is execution certainty, not a new strategic surprise. The proceeds are explicitly intended to fund the cash portion of Penumbra and related costs, and the offerings are expected to close on December 1, 2026. 〔1〕 〔2〕 Because the Penumbra deal and its cash-heavy structure were already public, the main new information is the scale and pricing of the borrowing rather than a change in strategy.
The trade-off is a meaningfully more leveraged transaction. Boston Scientific is not funding the purchase solely with these notes: the filing also points to short-term borrowings, credit-facility debt and cash on hand. If the acquisition fails, most of the notes carry a 101% special mandatory redemption feature, which limits stranded-debt risk but would still leave the company managing a costly financing process. 〔3〕
Bottom line: This is a financing milestone that makes the already-announced Penumbra acquisition more executable, but it does so by adding a large, relatively expensive debt burden. The business story advances modestly; it is not rewritten by the filing yet.,
Offerings close December 1, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!